Cargando…
Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review
Pulmonary Hypertension due to left heart disease is the most common type of Pulmonary Hypertension. Morbidity and mortality significantly increase once Pulmonary Hypertension is present. Treatment is aimed toward optimizing the underlying condition. Targeted therapy has been evaluated in small studi...
Autores principales: | Sanchez Palacios, Galo M., Schmidt, Cindy, Wichman, Tammy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545768/ https://www.ncbi.nlm.nih.gov/pubmed/33088478 http://dx.doi.org/10.1177/2045894020948780 |
Ejemplares similares
-
Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
por: Ovchinnikov, Artem, et al.
Publicado: (2022) -
Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease
por: Han, Bing, et al.
Publicado: (2018) -
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
por: Butrous, Ghazwan
Publicado: (2014) -
Role of Phosphodiesterase-5 Inhibitors in Acute Right Ventricular Failure Due to Pulmonary Embolism
por: Sharma, Munish, et al.
Publicado: (2019) -
Doppler estimates of pulmonary vascular resistance to phenotype pulmonary hypertension in heart failure
por: Venkateshvaran, Ashwin, et al.
Publicado: (2019)